A Comparison of Flow-mediated Dilatation and Peripheral Artery Tonometry for Measurement of Endothelial Function in Healthy Individuals and Patients with Peripheral Arterial Disease  by Allan, R.B. et al.
A Comparison of Flow-mediated Dilatation and Peripheral Artery Tonometry
for Measurement of Endothelial Function in Healthy Individuals and Patients
with Peripheral Arterial Disease
R.B. Allan a, C.L. Delaney a, M.D. Miller b, J.I. Spark a,*
a Department of Vascular Surgery, Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia
b Department of Nutrition and Dietetics, Flinders University, Bedford Park, South Australia, Australia* Co
Flinder
Tel.: þ
E-ma
1078
Elsevie
reserve
http:WHAT THIS PAPER ADDS
Flow-mediated dilatation (FMD) and peripheral artery tonometry (PAT) are both methods for assessing vascular
function that utilise the reactive hyperaemic response to transient occlusion. FMD measures predominantly
nitric oxide mediated dilatation whereas PAT measures a more complex range of mechanisms. In this study
there was a lack of correlation between the two methods and in addition there was no change in PAT for the
subjects with probable endothelial dysfunction. This suggests that PAT is not a sensitive method for testing
nitric-oxide dependent endothelial function and supports the concept that the two methods are measuring
different mechanisms. These ﬁndings highlight the importance of choosing an assessment method appropriate
for the function under investigation.Objective: Flow-mediated dilatation (FMD) and peripheral artery tonometry (PAT) are commonly used methods
for assessing endothelial function in a research setting but it is unclear how well they correlate. This study aimed
to compare and correlate these methods in patients with peripheral arterial disease (PAD) and in healthy
individuals.
Materials and methods: FMD and PATmeasurements were obtained as samples of convenience from 26 patients
with PAD and 25 healthy subjects. FMD was deﬁned as the percentage increase in the brachial artery diameter
after distal occlusion and PAT was measured using the reactive hyperaemia index (RHI).
Results: Patients with PAD had a signiﬁcantly lower FMD than healthy subjects (2.43% vs. 5.80%, p < 0.001). No
difference was found in RHI between the two groups. No correlation was found between the FMD and RHI in
subjects with PAD (r ¼ 0.284, p ¼ 0.160), in healthy subjects (r ¼ 0.153, p ¼ 0.464) or when both groups were
combined (r ¼ 0.174, p ¼ 0.22).
Conclusion: The lack of change in RHI in PAD patients suggests that PAT is not a sensitive measure of endothelial
function. The lack of correlation suggests that FMD and PAT are not interchangeable. PAT should not be used as
a substitute for FMD as a measure of endothelial function.
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The vascular endothelium provides an active biological
interface between the blood and all other tissues and has
a primary role in maintenance of the vascular environment
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//dx.doi.org/10.1016/j.ejvs.2012.12.002function, inﬂammatory responses and homeostasis in
response to mechanical and hormonal stimuli.1,2 Nitric
oxide (NO) is the most important of these agents and, as
well as being a powerful vasodilator, inhibits inﬂammatory
activity, vascular smooth muscle cell proliferation and
platelet adhesion and aggregation.3 These properties result
in NO having important anti-atherogenic functions.4 The
endothelium is of great interest in the study and treatment
of peripheral arterial disease (PAD) due to the central role
that alterations in these functions play in the development
of arterial disease.
Endothelial dysfunction refers to a loss of these
functions with a switching of the endothelial cells to an
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This results in a loss of vasodilatory ability and the
promotion of thrombosis, inﬂammation and cellular
proliferation.1,3 Endothelial dysfunction has been estab-
lished as an important early event in the pathogenesis of
atherosclerosis with changes in endothelial function
occurring well before the onset of clinically apparent
cardiovascular disease.2,6 Endothelial dysfunction has
been shown to predict cardiovascular events7e9 and to
correlate with known cardiovascular risk factors.10,11
Endothelial dysfunction can be identiﬁed by an impaired
endothelium dependent vasodilatory response to changes
in ﬂow or other stimuli.5,12
Many non-invasive methods for measuring endothelial
function have been investigated with two of the most
commonly used being ﬂow mediated dilatation (FMD) and
peripheral artery tonometry (PAT).
FMD is the most established and commonly used non-
invasive method for assessing endothelial function.5,12 The
FMD technique is based on the reactive hyperaemia
phenomenon of increased arterial blood ﬂow following
a period of transient arterial occlusion.13,14 This increase in
blood ﬂow results in an increase in shear stress on the
vessel wall and this induces the release of nitric oxide (NO)
by endothelial cells, causing vasodilatation.15 This response
is termed NO-mediated ﬂow mediated dilatation and is
typically measured in the brachial artery. It has become
apparent that the position of the occlusive cuff has
a signiﬁcant effect on FMD.16,17 Proximal, upper arm,
occlusion causes a greater dilatation16,18 but this is not
solely a NO-mediated response.17 Distal, forearm, occlusion
causes a lesser, but more speciﬁcally NO-mediated, dilata-
tion17 and has recently become the recommended FMD
method.14,15,19
PAT is a more recently developed method that has been
used to measure endothelial function.20,21 PAT uses pneu-
matic ﬁnger probes to measure digital arterial pulse wave
amplitude when reactive hyperaemia is induced. Ease of
use, standardised methodology and the availability of vali-
dated cut-off thresholds to predict future cardiovascular
events21 have encouraged the use of PAT in studying
endothelial function.22
The degree to which the two tests correlate with one
another is not clear and the use of different occlusion
methods for FMD has confused the available evidence, with
most studies investigating correlation using proximal
occlusion FMD20,23e27 and fewer studies using the currently
recommended technique of distal occlusion.28e30
Comparison studies of PAT and distal occlusion FMD have
investigated normal individuals28,29 or a community based
population30 but no studies comparing PAT and FMD have
been reported in a population with PAD.
Due to the importance of endothelial dysfunction in the
development of PAD this study was performed to 1) identify
whether a detectable difference exists in subjects with
established PAD and in healthy individuals with respect to
distal occlusion FMD and PAT and 2) assess whether there
was a correlation between the two methods.MATERIALS AND METHODS
Participant selection
Data was collected from participants enrolled in two studies
in which FMD and PAT were performed as tests of endo-
thelial function as part of the investigation of speciﬁc
interventions.
The ﬁrst study was investigating the effects on endo-
thelial function of moderate dose ﬁsh oil on healthy
participants with a parent with PAD. The second study was
investigating the effects of two different exercise regimes
on participants with claudication. FMD and PAT tests were
performed at baseline, at 6 weeks (for the ﬁsh oil study
only) and at the 12 week conclusion of the studies. Inclusion
and exclusion criteria for each study are presented in
Table 1.
This analysis was limited to the baseline tests because of
the non-independent nature of the follow-up measure-
ments and the risk of confounding variables due to poten-
tial differing effects of the interventions on each test. The
outcomes of the interventions are not reported as the
studies are on-going and beyond the scope of this study.
Due to the operator dependent nature of FMD, test-
retest reproducibility testing of pre-occlusion brachial artery
diameter was performed. Brachial artery diameters were
acquired from a group of healthy volunteers (n ¼ 10) on
two separate occasions, 48 h apart.
This study was approved by the Southern Adelaide
Clinical Human Research Ethics Committee. All participants
provided written informed consent for the measurement of
FMD and PAT prior to commencement of data collection.Peripheral arterial tonometry
Participants were instructed to fast for eight hours, refrain
from caffeine, alcohol and tobacco and avoid exercise for
eight hours prior to testing. PAT tests were performed using
an EndoPAT device (Itamar Medical Ltd, Caesarea, Israel),
following the manufacturer’s guidelines, in a quiet, dimmed
and temperature controlled room. The occlusion cuff was
placed above the elbow on the left arm and the ﬁnger tip
plethysmography probes were placed on the index ﬁngers
of each hand. The pulse wave amplitude was continuously
recorded by the device for the duration of the test. The test
commenced with a 5 min baseline period, followed by
5 min with the cuff inﬂated to 250 mmHg to achieve total
brachial artery occlusion and then a ﬁnal 5 min period of
reactive hyperaemia following the cuff release.
The 15 min recordings were then analysed using the
device’s proprietary software and the reactive hyperaemia
index (RHI) was calculated by the device using the method
previously described by McCrea.31Brachial artery ultrasound ﬂow-mediated dilatation
FMD was performed and measured using techniques
consistent with published guidelines.14,19 FMD testing was
performed 15 min after the completion of the PAT test as
this time interval between arm occlusion episodes has been
Table 1. Inclusion and exclusion criteria for participants in the intervention studies used as sample groups.
Fish oil intervention on healthy participants Exercise intervention on patients with PAD
Inclusion criteria Parent with PAD Radiographic evidence of infra-inguinal PAD
with history consistent with intermittent
claudication
Exclusion criteria Clinical history of coronary, cerebral or peripheral
arterial disease or ankle-brachial pressure
index <0.9
Vasoactive medication known to impact
on endothelial function
Seafood allergy
Taking therapeutic doses of ﬁsh oil
Inability to communicate effectively to give
consent
Treatment doses of anti-thrombotic agents
Dual anti-platelet therapy
Diagnosis of a bleeding disorder
Aorto-iliac occlusive disease
Lower limb ischaemic rest pain or tissue loss
Recent (<12 months) peripheral vascular
intervention
Pre-existing respiratory morbidities limited
exercise capacity
Contra-indications to standard “best medical
therapy”
Inability to communicate effectively to give
consent
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performed with a SonoSite M-Turbo ultrasound system
(SonoSite, Inc, Bothel, USA) with a 6e13 MHz broadband
linear array transducer. All tests were performed by two
operators experienced in the technique (RA and CD). With
the participant supine, the right arm was placed in a -
supporting cradle, a blood pressure cuff placed around the
forearm and the ultrasound transducer was placed on the
arm proximal to the elbow with the aid of a sterotactic
stand. A 3 lead ECG was connected to the ultrasound
machine to enable display of the cardiac cycle.
A 30 s baseline period of scanning of the brachial artery
was recorded prior to cuff inﬂation. The cuff was then
inﬂated to 250 mmHg for 5 min to achieve total brachial
artery occlusion. Recording recommenced at 15 s post
occlusion and continued for three minutes.
The pre and post occlusion cine clips were then trans-
ferred to a computer for measurement by automated edge
detection software (Brachial Artery Analyser, MIA-LLC,
Coralville, USA). All measurements were obtained during
diastole. The point of maximum dilatation was identiﬁed
and the maximum diameter was obtained by averaging 5
images from consecutive cardiac cycles. The FMD was
calculated using the equation:
FMD (%) ¼ [(peak diameterbaseline diameter)/baseline
diameter]  100.14Table 2. Characteristics of the sample groups.
Healthy subjects
(n ¼ 25)
Subjects with
peripheral arterial
disease
(n ¼ 26)
Mean age (range)
years
44.96 (17e67) 72.61 (58e90)
Gender: male:female 11:14 19.7
Mean BMI (range) 29.2 (21.5e40.2) 29.4 (23.1e43.6)
FMD% (SD) 5.80 (3.57) 2.43 (2.47)
RHI (SD) 1.81 (0.55) 1.83 (0.83)
BMI: body mass index, FMD: ﬂow-mediated dilatation, RHI:
reactive hyperaemia index, SD: standard deviation.Statistical analyses
Data were analysed using the SPSS for Windows statistical
package version 19 (SPSS Inc, Chicago, IL, USA).
Age, gender, body-mass index (BMI), FMD and RHI were
presented for each sample.
Student’s t-test was performed to assess for signiﬁcant
differences in either FMD or RHI between the healthy and
PAD samples.
Correlation between FMD and RHI was assessed using
Pearson correlation coefﬁcient and illustrated using scatter
plots. Correlation between FMD and RHI was tested for
each sample and for all participants grouped as one sample.Reproducibility of the pre-occlusion brachial artery
diameter measurement was assessed by calculating the
intra-class correlation coefﬁcient (ICC) for the ﬁrst and
second measurements in the group of healthy volunteers.
All tests were two-tailed and the level of statistical
signiﬁcance was set at p <0.05.RESULTS
The sample populations consisted of 25 healthy subjects in
the ﬁsh oil intervention study and 26 participants with PAD
in the exercise intervention study.
The age, gender and BMI, FMD% and RHI are presented
in Table 2 for each group. While BMI was similar between
the two groups, age and gender characteristics were
signiﬁcantly different with the PAD population being older
and predominantly male, matching the known characteris-
tics of patients with PAD. No subjects were on nitrate-based
medications. None of the healthy subjects were on statins
while all subjects with PAD were on statins. A box plot
(Fig. 1A) of RHI for both groups demonstrated similar
distributions and t-testing revealed no difference in RHI
between the healthy and PAD groups (p ¼ 0.944). The box
plot for FMD (Fig. 1B) suggested that the FMD for the PAD
group was lower than that found in the healthy subjects
and this was conﬁrmed by a signiﬁcant difference in the
t-test (p < 0.001).
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Figure 1. Box and whisker plots showing distribution of results for
subjects with PAD and healthy subjects, (A) RHI and (B) FMD%.
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Figure 2. Scatterplots of FMD and RHI for (A) healthy subjects, (B)
subjects with PAD and (C) all subjects.
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Scatterplots of FMD and RHI for both the healthy group
and the PAD group (Fig. 2A and B) suggested no evidence
of correlation and this was conﬁrmed by the Pearson
correlation coefﬁcients of r ¼ 0.153 (p ¼ 0.464) for the
healthy group and r ¼ 0.284 (p ¼ 0.160) for the PAD
group. A scatterplot of FMD and RHI for a sample
combining both groups also suggested no evidence of
correlation (Fig. 2C), with a correlation coefﬁcient of 0.174
(p ¼ 0.22) conﬁrming no signiﬁcant correlation between
the FMD and RHI.Reproducibility testing
The mean pre-occlusion diameter of the brachial artery was
3.885 mm for the ﬁrst measurement and 3.931 mm for the
second, giving a mean difference of 1.18%. The ICC of 0.989
(p < 0.001) indicated excellent agreement between ﬁrst
and second measurements.DISCUSSION
This is the ﬁrst study to compare the performance of FMD
and PAT in healthy individuals and subjects with established
PAD and the ﬁrst to investigate whether FMD and PAT
correlate in subjects with PAD. In the present study no
correlation was found between FMD and PAT in either the
R.B. Allan et al. 267healthy or PAD groups, or when the two groups were
combined into one sample. The evidence base regarding
correlation of FMD and PAT is small and contradictory. Of
the nine studies identiﬁed that reported the results of
correlation testing between FMD and PAT, six reported
weak to moderate (r ¼ 0.17e0.57) but signiﬁcant correla-
tion20,23e25,27,29 while three reported no signiﬁcant corre-
lation.26,28,30 Technical and sample group differences need
to be considered when interpreting the results of the
present study to those of the available literature.
The position of the occlusion cuff is an important tech-
nical difference that has been shown to have a marked
effect on the percentage dilatation obtained with FMD.16,17
Previous studies use either occlusion proximal to the
transducer in the upper arm or distal occlusion in the
forearm. Occlusion proximal to the transducer has been
shown to cause a greater degree of vessel dilatation with
FMD.16,17 This has been attributed to non-NO-mediated
factors contributing to the reactive hyperaemia response
with ischaemia induced vasodilatory metabolites and a loss
of myogenic tone being proposed as likely mechanisms.17
This phenomenon has led to recommendations that FMD
should be performed with occlusion at the forearm to
ensure that the measured response is primarily NO-medi-
ated in origin.14,19 This also has the effect of reducing the
magnitude of the dilatation observed with FMD, an
important factor when comparing results from different
studies. By its nature PAT requires a proximal occlusion and
this may be one of the reasons why non-NO-mediated
mechanisms appear to contribute the hyperaemic response
measured by PAT.33 It would be reasonable to expect that
proximal occlusion FMD might correlate better with PAT
than distal FMD. The present study, and previous studies of
correlation, would tend to support this conclusion with ﬁve
of the six studies that used proximal occlusion FMD
demonstrating a correlation with PAT while three of four
studies (if the present study is included) that used distal
forearm occlusion ﬁnding no evidence of correlation.
Although recent guidelines14,19 have recommended that
the distal occlusion technique should be used to measure
NO-mediated endothelial function, the FMD literature
remains a mixture of both techniques, necessitating care
when reviewing the conclusions of studies involving FMD.
In addition to variation resulting from the method of
occlusion, there are also differences in the physiology of the
vascular beds being tested that need to be considered. It
has been shown that there are differences in the response
of resistive and conduit vessels to reactive hyperaemia.29,34
PAT measures the response to reactive hyperaemia in the
digits, a vasculature bed which is a combination of macro
and micro-circulation with a signiﬁcant role played by
arteriovenous anastomoses which are regulated primarily
by the sympathetic nervous system.29 NO makes only
a partial contribution to reactive hyperaemia with PAT33
suggesting that the sympathetic nervous system plays
a signiﬁcant role in this response. In addition skin reactive
hyperaemia has been shown to be independent of NO
mediation.29 FMD measures the hyperaemic response ina large conduit vessel with stimulus for dilatation being the
increased shear stress observed on release of the occlusion
cuff. This dilatation, in contrast to PAT, has been shown to
be predominantly NO-mediated.17
Because endothelial dysfunction is a precursor to the
development of atherosclerosis,2,6 it would be expected
that measures of endothelial function would be reduced in
subjects with PAD, and this is supported by observational
evidence.35 Endothelial function has also been demon-
strated to reduce with age.36 The results of FMD testing in
the present study support this by demonstrating signiﬁ-
cantly reduced FMD in subjects with PAD, who were also
older, compared with healthy individuals. The surprising
result from this study is that there is no difference in RHI
between healthy subjects and those with PAD. This has
not been previously reported and supports the theory that
PAT measures a more complex range of factors, with
NO-mediated effects being less predominant. It may be that
there is preservation of sympathetic and myogenic
responses to ischaemia in patients with PAD and that
PAT may be less sensitive as a measure of NO-mediated
endothelial function.
Operator dependent measurement variability is unlikely
to be a factor in these ﬁndings. Reproducibility testing
demonstrated very good repeatability for the measurement
of the brachial artery and the EndoPAT machine uses an
automated software algorithm that calculates the RHI,
removing operator variables. The study methodology
controlled for subject preparation and timing, ensuring that
FMD and PAT were performed under the same conditions.
A further source of variability could be vasoactive
medications. None of these patients were taking nitrate
based pharmacotherapy, while all the subjects with PAD,
but none of the healthy subjects, were on statins, which are
known to improve endothelial function. FMD and PAT
results may have been improved by statin therapy but the
results for the PAD group were still signiﬁcantly lower that
found in the healthy group.
A limitation of the present study is that FMD and RHI
results from subjects with PAD were compared to a group
of healthy individuals that were not age and gender
matched. Age has been shown to have a signiﬁcant negative
correlation with endothelial function36 and it is likely that
some of the reduction in FMD found in the PAD sample may
be due to the effects of age. This limitation does not does
not alter the signiﬁcance of the lack of difference in RHI
between the healthy and PAD groups. The subjects with
PAD clearly have reduced endothelial function and the
inability of PAT to identify this is important regardless of the
speciﬁc cause of the endothelial dysfunction.
Another potential limitation may be that the subjects
were obtained from pre-existing interventional studies
rather than being speciﬁcally recruited for this study,
however the speciﬁcs of these interventions would have
had no effect on the analysis of the FMD and PAT results as
only the baseline measurements were used. Despite
extensive study, endothelial function testing remains
a research technology. It has been shown to be a valid
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reported at an individual level37,38 has limited the trans-
lation of these methods to clinical practice.
This study showed no correlation between FMD and PAT,
in both healthy subjects and those with peripheral arterial
disease. This is most likely due to differences between the
methods in cuff position relative to measurement site and
circulatory physiology of the vascular beds. The lack of
standardisation of cuff position in FMD is an important
consideration when reviewing the literature of endothelial
function assessment.
Furthermore, the lack of change in hyperaemic response
measured by PAT in older subjects with PAD suggests that it
is not a sensitive method for measuring NO-mediated
endothelial function.
Whilst PAT, due to its ease of use and simplicity, is an
attractive option as a research tool, caution is required
when considering it as a substitute for FMD as a measure of
endothelial function, particular if NO-mediated endothelial
function is the phenomena under investigation.
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